Wild type NRAS
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab | |
| EMA (1) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab, Irinotecan | |
| EMA (1) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab, Fluorouracil, Oxaliplatin | |
| EMA (1) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Oxaliplatin, Panitumumab | |
| EMA (2) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Irinotecan, Panitumumab | |
| EMA (1) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Panitumumab | |
| FDA (2) | HER2-positive, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Trastuzumab, Tucatinib |